Gadolinium Contrast for Magnetic Resonance Imaging final
Gadolinium_Contrast_for_Magnetic_Resonance_Imaging_final
File: Gadolinium_Contrast_for_Magnetic_Resonance_Imaging_final.pdfGadolinium
Gadolinium Deposition: Information for Providers
The purpose of this document is to provide an update on the recently reported phenomenon of gadolinium deposition in the brain, and to
provide guidance to referring physicians ordering gadolinium-enhanced MRI studies at UW Health.
Gadolinium Deposition: Information for Patients
Patient information sheet about gadolinium-based contrast agents
File: for-patients-gadolinium-contrast-for-magnetic-resonance-imaging.pdfGadolinium Tables
Extended table of clinically relevant information regarding gadolinium-based contrast agents
File: mri-gadolinium-tables.pdfHow to Calculate Volume of Gadolinium-Based Contrast Agents
Introduction to the calculations used to generate correct volume of any gadolinium-based contrast agent
File: how-to-calculate-volume-of-gadolinium-based-contrast-agents.pdfGadolinium-Based Contrast Dosing Charts
charts showing standard and maximum dosages, and dosages based on weight for gadolinium-based contrast agents
File: gadolinium-based-contrast-dosing-charts.pdfGadolinium and Breastfeeding
The following memo provides an update on the UW-Madison Department of Radiology policy for scanning
patients who are breastfeeding
MRI in Pregnancy
The following memo provides an interval update on the UW-Madison Department of Radiology policy for
scanning pregnant patients, including the use of gadolinium contrast agents, approved on 3/16/16 by the UW MRI Safety Committee.
Gadolinium-enhanced MRI/A and Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis
This document describes modified screening procedures for mitigating the risk of nephrogenic
systemic fibrosis (NSF) in patients with renal failure undergoing gadolinium-enhanced MRI.